Accessibility Menu
 
TScan Therapeutics logo

TScan Therapeutics

(NASDAQ) TCRX

Current Price$1.25
Market Cap$72.72M
Since IPO (2021)-88%
5 YearN/A
1 Year-8%
1 Month+20%

TScan Therapeutics Financials at a Glance

Market Cap

$72.72M

Revenue (TTM)

$8.15M

Net Income (TTM)

$124.31M

EPS (TTM)

$-1.00

P/E Ratio

-1.21

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.25

Volume

13,579

Open

$1.22

Previous Close

$1.25

Daily Range

$1.20 - $1.25

52-Week Range

$0.88 - $2.57

TCRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TScan Therapeutics

Industry

Biotechnology

Employees

142

CEO

Gavin MacBeath, PhD

Headquarters

Waltham, MA 02451, US

TCRX Financials

Key Financial Metrics (TTM)

Gross Margin

82%

Operating Margin

-16%

Net Income Margin

-15%

Return on Equity

-71%

Return on Capital

-71%

Return on Assets

-62%

Earnings Yield

-82.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$72.72M

Shares Outstanding

60.10M

Volume

13.58K

Avg. Volume

823.54K

Financials (TTM)

Gross Profit

$7.46M

Operating Income

$135.81M

EBITDA

$132.95M

Operating Cash Flow

$135.32M

Capital Expenditure

$4.41M

Free Cash Flow

$139.73M

Cash & ST Invst.

$152.41M

Total Debt

$94.14M

TScan Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$72.72M

N/A

Market Cap/Employee

$363.61K

N/A

Employees

200

N/A

Net Income

$28.67M

+16.0%

EBITDA

$29.14M

+11.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$68.17M

-55.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$52.45M

-43.0%

Short Term Debt

$7.44M

+49.6%

Return on Assets

-61.54%

N/A

Return on Invested Capital

-70.71%

N/A

Free Cash Flow

$24.35M

+37.8%

Operating Cash Flow

$24.28M

+35.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PMVPPMV Pharmaceuticals, Inc.
$1.45+5.84%
XBITXBiotech Inc.
$2.55+0.00%
ACRVAcrivon Therapeutics, Inc. Common Stock
$2.09+0.48%
ACETAdicet Bio, Inc.
$8.55+0.47%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$113.01+0.04%
NOKNokia
$13.19-0.02%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.14-0.12%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.58+0.05%

Questions About TCRX

What is the current price of TScan Therapeutics?

TScan Therapeutics is trading at $1.25 per share.

What is the 52-week range for TScan Therapeutics?

Over the past 52 weeks, TScan Therapeutics has traded between $0.88 and $2.57.

How much debt does TScan Therapeutics have?

As of the most recent reporting period, TScan Therapeutics reported total debt of $94.14M.

How much cash does TScan Therapeutics have on hand?

TScan Therapeutics reported $152.41M in cash and cash equivalents in its most recent financial results.

What is TScan Therapeutics’s dividend yield?

TScan Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.